search
Back to results

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
HCTZ + Amlodipine
Valsartan/HCTZ
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Obesity, hypertension, valsartan/hydrochlorothiazide

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 40 years of age or older
  • Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg
  • Central (abdominal) obesity

Exclusion Criteria:

  • Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg
  • Currently taking more then 3 medications to treat high blood pressure
  • Inability to stop all current blood pressure medications if any up to 4 weeks
  • History of Type 1 or Type 2 diabetes
  • History of stroke, mini-stroke (transient ischemic attack) or heart attack within the last 6 months
  • History of or current diagnosis of congestive heart failure
  • History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma
  • Women who are pregnant or nursing
  • Alcohol or drug abuse within the last 2 years

Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Terence T. Hart, MD
  • Westlake Medical Research
  • Oklahoma Cardiovascular & Hypertension
  • Northeast Tarrant Internal Medicine Assoc
  • Frandsen Family Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

valsartan/HCTZ

HCTZ +Amlodipine

Arm Description

Outcomes

Primary Outcome Measures

Change in Mean Sitting Systolic Blood Pressure (MSSBP)

Secondary Outcome Measures

Change in Mean Sitting Diastolic Blood Pressure (MSDBP)
Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg
Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg
Change From Baseline in Postprandial Glucose
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Change From Baseline in Postprandial Insulin
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Change From Baseline in Postprandial Non-esterified Fatty Acids
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test

Full Information

First Posted
February 23, 2007
Last Updated
April 19, 2017
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00439738
Brief Title
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
Official Title
A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
December 2006 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure [MSSBP] >150 mmHg) patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Obesity, hypertension, valsartan/hydrochlorothiazide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
412 (Actual)

8. Arms, Groups, and Interventions

Arm Title
valsartan/HCTZ
Arm Type
Experimental
Arm Title
HCTZ +Amlodipine
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
HCTZ + Amlodipine
Intervention Description
12.5 mg HCTZ capsules 25 mg HCTZ capsules 5 mg amlodipine capsules 10 mg amlodipine capsules
Intervention Type
Drug
Intervention Name(s)
Valsartan/HCTZ
Intervention Description
160 mg film-coated valsartan tablets 320 mg film-coated valsartan tablets 12.5 mg HCTZ capsules 25 mg HCTZ capsules
Primary Outcome Measure Information:
Title
Change in Mean Sitting Systolic Blood Pressure (MSSBP)
Time Frame
Baseline to Week 8
Secondary Outcome Measure Information:
Title
Change in Mean Sitting Diastolic Blood Pressure (MSDBP)
Time Frame
Baseline to Weeks 4, 8, 12 and 16
Title
Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)
Description
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg
Time Frame
Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
Title
Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)
Description
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg
Time Frame
Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
Title
Change From Baseline in Postprandial Glucose
Description
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Time Frame
Week 16
Title
Change From Baseline in Postprandial Insulin
Description
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Time Frame
Week 16
Title
Change From Baseline in Postprandial Non-esterified Fatty Acids
Description
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Time Frame
Week 16

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 40 years of age or older Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg Central (abdominal) obesity Exclusion Criteria: Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg Currently taking more then 3 medications to treat high blood pressure Inability to stop all current blood pressure medications if any up to 4 weeks History of Type 1 or Type 2 diabetes History of stroke, mini-stroke (transient ischemic attack) or heart attack within the last 6 months History of or current diagnosis of congestive heart failure History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma Women who are pregnant or nursing Alcohol or drug abuse within the last 2 years Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Chair
Facility Information:
Facility Name
Terence T. Hart, MD
City
Muscle Shoals
State/Province
Alabama
ZIP/Postal Code
35662
Country
United States
Facility Name
Westlake Medical Research
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
Oklahoma Cardiovascular & Hypertension
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73132
Country
United States
Facility Name
Northeast Tarrant Internal Medicine Assoc
City
Euless
State/Province
Texas
ZIP/Postal Code
76040
Country
United States
Facility Name
Frandsen Family Medicine
City
Port Orchard
State/Province
Washington
ZIP/Postal Code
98366
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22747613
Citation
Deedwania PC, Zappe DH, Egan BM, Purkayastha D, Samuel R, Sowers JR. Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide? J Clin Hypertens (Greenwich). 2012 Jul;14(7):415-21. doi: 10.1111/j.1751-7176.2012.00635.x. Epub 2012 Apr 26.
Results Reference
derived
PubMed Identifier
22248871
Citation
Ofili EO, Zappe DH, Purkayastha D, Samuel R, Sowers JR. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. Am J Ther. 2013 Jan;20(1):2-12. doi: 10.1097/MJT.0b013e318230ae66.
Results Reference
derived
PubMed Identifier
20498618
Citation
Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010 Aug;28(8):1761-9. doi: 10.1097/HJH.0b013e32833af380.
Results Reference
derived

Learn more about this trial

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

We'll reach out to this number within 24 hrs